AbbVie In Hot Seat Over HCV Drugs' Serious Liver Injury Risk
This article was originally published in The Pink Sheet Daily
After adverse event reports in patients with underlying advanced liver damage, FDA requires AbbVie to add risk language to Viekira Pak and Technivie labels. AbbVie may not see much long-term damage, but Merck likely will gain more traction when it enters the hepatitis C market.
You may also be interested in...
FDA imposes boxed warning on labels for hepatitis C drugs in response to reports of hepatitis B reactivation, including fatal cases.
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Keeping Track: US FDA Clears Bylvay, Fexinidazole, Gives Retifanlimab CRL; JAK Inhibitor Class Delays
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker